JP5042411B2 - 抗腫瘍剤としてのエストロン誘導体の使用 - Google Patents

抗腫瘍剤としてのエストロン誘導体の使用 Download PDF

Info

Publication number
JP5042411B2
JP5042411B2 JP2000614980A JP2000614980A JP5042411B2 JP 5042411 B2 JP5042411 B2 JP 5042411B2 JP 2000614980 A JP2000614980 A JP 2000614980A JP 2000614980 A JP2000614980 A JP 2000614980A JP 5042411 B2 JP5042411 B2 JP 5042411B2
Authority
JP
Japan
Prior art keywords
cells
group
sulfamate
compound
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000614980A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002543114A5 (enExample
JP2002543114A (ja
Inventor
マイケル ジョン リード，
バリー ビクター ロイド ポッター，
Original Assignee
ステリックス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9910166.9A external-priority patent/GB9910166D0/en
Priority claimed from GB0002113A external-priority patent/GB0002113D0/en
Application filed by ステリックス リミテッド filed Critical ステリックス リミテッド
Publication of JP2002543114A publication Critical patent/JP2002543114A/ja
Publication of JP2002543114A5 publication Critical patent/JP2002543114A5/ja
Application granted granted Critical
Publication of JP5042411B2 publication Critical patent/JP5042411B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2000614980A 1999-04-30 2000-04-28 抗腫瘍剤としてのエストロン誘導体の使用 Expired - Fee Related JP5042411B2 (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB9910166.9A GB9910166D0 (en) 1999-04-30 1999-04-30 Use
GB9910166.9 1999-04-30
US13952099P 1999-06-16 1999-06-16
US60/139,520 1999-06-16
GB60/139,520 2000-01-28
GB0002113A GB0002113D0 (en) 2000-01-28 2000-01-28 Use
GB0002113.9 2000-01-28
PCT/GB2000/001661 WO2000066095A2 (en) 1999-04-30 2000-04-28 Use of estrone derivatives as antitumour agents

Publications (3)

Publication Number Publication Date
JP2002543114A JP2002543114A (ja) 2002-12-17
JP2002543114A5 JP2002543114A5 (enExample) 2007-04-26
JP5042411B2 true JP5042411B2 (ja) 2012-10-03

Family

ID=27255503

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000614980A Expired - Fee Related JP5042411B2 (ja) 1999-04-30 2000-04-28 抗腫瘍剤としてのエストロン誘導体の使用

Country Status (7)

Country Link
US (1) US8207152B2 (enExample)
EP (1) EP1173182A2 (enExample)
JP (1) JP5042411B2 (enExample)
AU (1) AU783910B2 (enExample)
IL (2) IL145995A0 (enExample)
NZ (1) NZ515061A (enExample)
WO (1) WO2000066095A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US20040127473A1 (en) * 1996-12-05 2004-07-01 Reed Michael John Compound
GB9913536D0 (en) * 1999-06-10 1999-08-11 Sterix Ltd Use
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US20020106348A1 (en) * 2000-07-12 2002-08-08 Peng Huang Cancer therapeutics involving the administration of 2-methoxyestradiol and an agent that increases intracellular superoxide anion
GB0020498D0 (en) 2000-08-18 2000-10-11 Sterix Ltd Compound
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US6995278B2 (en) 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
AU8838601A (en) * 2000-11-27 2002-06-03 Entremed Inc Antiangiogenic agents
GB0113920D0 (en) 2001-06-07 2001-08-01 Sterix Ltd Composition
US8026229B2 (en) 2001-08-13 2011-09-27 Sterix Limited Antitumor-active 2-alkoxyestradiol sulfamates
DE10139494A1 (de) * 2001-08-13 2003-03-06 Jenapharm Gmbh Antitumor wirksame 2-Alkoxyestradiolsulfamate
AU2002358755A1 (en) 2001-12-21 2003-07-09 Schering Aktiengesellschaft Industrially applicable process for the sulfamoylation of alcohols and phenols
DK1608671T3 (da) 2003-03-24 2010-05-10 Sterix Ltd Østrogenderivater som inhibitorer af steroidsulfatase
GB0306717D0 (en) * 2003-03-24 2003-04-30 Sterix Ltd Compound
JP2006526025A (ja) 2003-05-28 2006-11-16 エントレメッド インコーポレイテッド 抗血管新生剤
JP2007529426A (ja) 2004-03-12 2007-10-25 エントレメッド インコーポレイテッド 抗血管新生薬
GB0421106D0 (en) * 2004-09-22 2004-10-27 Sterix Ltd Compound
AU2007227256B2 (en) 2006-03-20 2012-10-04 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
JP2024542821A (ja) * 2021-12-06 2024-11-15 カシーヴ バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー 癌治療のための化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9003939D0 (en) * 1990-02-21 1990-04-18 Imperial College Sulphatase inhibitors
GB9118478D0 (en) * 1991-08-29 1991-10-16 Imperial College Steroid sulphatase inhibitors
US6476011B1 (en) 1991-08-28 2002-11-05 Sterix Limited Methods for introducing an estrogenic compound
GB9625334D0 (en) * 1996-12-05 1997-01-22 Imperial College Compound
GB9603325D0 (en) 1996-02-16 1996-04-17 Imperial College A compound
GB9118465D0 (en) * 1991-08-29 1991-10-16 Imperial College Steroid sulphatase inhibitors
AU2225597A (en) 1996-03-05 1997-09-22 Imperial College Of Science, Technology And Medicine Compounds with a sulfamate group
EP0934949A1 (en) 1996-09-12 1999-08-11 Teikoku Hormone Mfg. Co., Ltd. 3-substituted-d-homo-1,3,5,(10)-estratriene derivatives
US5763492A (en) * 1996-10-01 1998-06-09 Duguesne University Of The Holy Ghost Methods for effecting memory enhancement mediated by non-steroidal sulfatase inhibitors
US5880115A (en) 1997-07-18 1999-03-09 Duquesne University Of The Holy Ghost Steroid sulfatase inhibitors and methods for making and using the same
GB2331988B (en) * 1997-12-04 2003-04-16 Imperial College Polycyclic sulphamate inhibitors or oestrone sulphatase
GB2331987B (en) * 1997-12-04 2002-11-27 Imperial College Polycyclic sulphamate inhibitors of oestrone sulphatase
ES2310943T3 (es) * 1998-06-10 2009-01-16 Sterix Limited Composicion farmaceutica con factor de necrosis tumoral a y 2-metoxiestrona-3-o-sulfamato para la inhibicion de la estrona sulfatasa.
GB9913536D0 (en) * 1999-06-10 1999-08-11 Sterix Ltd Use
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies

Also Published As

Publication number Publication date
WO2000066095A3 (en) 2001-08-09
US20060122161A1 (en) 2006-06-08
NZ515061A (en) 2004-04-30
US8207152B2 (en) 2012-06-26
EP1173182A2 (en) 2002-01-23
IL145995A0 (en) 2002-07-25
AU783910B2 (en) 2005-12-22
IL145995A (en) 2009-11-18
AU4766800A (en) 2000-11-17
JP2002543114A (ja) 2002-12-17
WO2000066095A2 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
JP5042411B2 (ja) 抗腫瘍剤としてのエストロン誘導体の使用
US6054446A (en) Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
JP2008120839A (ja) 抗−分裂剤としてのエストロゲン性化合物
AU2001288386B2 (en) 2-substituted estrogens as antiangiogenic agents
JP2002517449A (ja) エストロンスルファターゼの阻害のための腫瘍壊死因子ａおよび２−メトキシエストロン−３−ｏ−スルファメートを有する薬学的組成物
US6995278B2 (en) Antiangiogenic agents
AU2001288386A1 (en) 2-substituted estrogens as antiangiogenic agents
US7135581B2 (en) Antiangiogenic agents
JP5144543B2 (ja) ステロイドスルファターゼインヒビターとしてのステロイド性化合物
ES2250224T3 (es) Compuestos halogenos de sulfamato, fosfonato, tiofosfonato, sulfonato y sulfonamida como inhibidores de sulfatasa esteoride.
US20050192258A1 (en) Antiangiogenic agents
US7078395B1 (en) Methods for treating or preventing cancer by preventing, inhibiting or arresting cell cycling
WO2006032885A2 (en) 2-substituted estrogen sulphamates for inhibition of steroid sulphatase
AU2005225148B2 (en) Use
ZA200108363B (en) Use.
ES2314760T3 (es) Compuestos esteroideos para la inhibicion de la sulfatasa esteroidea.
WO2003073985A2 (en) New methods of using antiangiogenic agents
JP2002518517A (ja) 不飽和１４，１５−シクロプロパノ−アンドロスタン、その製造法および該化合物を含有する製薬学的調製剤
JP2005501849A (ja) 抗腫瘍性として活性な２−アルコキシエストラジオール・スルファメート

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101111

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120229

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120516

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120530

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120622

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120711

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150720

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees